<- Go Home
Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Market Cap
$159.0M
Volume
508.1K
Cash and Equivalents
$4.0M
EBITDA
-$21.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$2.60
52 Week Low
$1.04
Dividend
N/A
Price / Book Value
2.9K
Price / Earnings
-7.89
Price / Tangible Book Value
2.9K
Enterprise Value
$155.5M
Enterprise Value / EBITDA
-7.44
Operating Income
-$21.1M
Return on Equity
924.32%
Return on Assets
-115.96
Cash and Short Term Investments
$4.0M
Debt
$456.0K
Equity
$52.0K
Revenue
N/A
Unlevered FCF
-$5.5M
Sector
Biotechnology
Category
N/A